Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 1
2000 2
2001 1
2002 2
2003 17
2004 8
2005 8
2006 4
2007 3
2008 3
2009 4
2010 1
2011 5
2012 6
2013 13
2014 7
2015 10
2016 11
2017 10
2018 11
2019 19
2020 18
2021 19
2022 2
Text availability
Article attribute
Article type
Publication date

Search Results

161 results
Results by year
Filters applied: . Clear all
Page 1
ESMO Management and treatment adapted recommendations in the COVID-19 era: Breast Cancer.
de Azambuja E, Trapani D, Loibl S, Delaloge S, Senkus E, Criscitiello C, Poortman P, Gnant M, Di Cosimo S, Cortes J, Cardoso F, Paluch-Shimon S, Curigliano G. de Azambuja E, et al. Among authors: di cosimo s. ESMO Open. 2020 May;5(Suppl 3):e000793. doi: 10.1136/esmoopen-2020-000793. ESMO Open. 2020. PMID: 32439716 Free PMC article. Review.
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial.
Baselga J, Bradbury I, Eidtmann H, Di Cosimo S, de Azambuja E, Aura C, Gómez H, Dinh P, Fauria K, Van Dooren V, Aktan G, Goldhirsch A, Chang TW, Horváth Z, Coccia-Portugal M, Domont J, Tseng LM, Kunz G, Sohn JH, Semiglazov V, Lerzo G, Palacova M, Probachai V, Pusztai L, Untch M, Gelber RD, Piccart-Gebhart M; NeoALTTO Study Team. Baselga J, et al. Among authors: di cosimo s. Lancet. 2012 Feb 18;379(9816):633-40. doi: 10.1016/S0140-6736(11)61847-3. Epub 2012 Jan 17. Lancet. 2012. PMID: 22257673 Free PMC article. Clinical Trial.
Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial.
Piccart-Gebhart M, Holmes E, Baselga J, de Azambuja E, Dueck AC, Viale G, Zujewski JA, Goldhirsch A, Armour A, Pritchard KI, McCullough AE, Dolci S, McFadden E, Holmes AP, Tonghua L, Eidtmann H, Dinh P, Di Cosimo S, Harbeck N, Tjulandin S, Im YH, Huang CS, Diéras V, Hillman DW, Wolff AC, Jackisch C, Lang I, Untch M, Smith I, Boyle F, Xu B, Gomez H, Suter T, Gelber RD, Perez EA. Piccart-Gebhart M, et al. Among authors: di cosimo s. J Clin Oncol. 2016 Apr 1;34(10):1034-42. doi: 10.1200/JCO.2015.62.1797. Epub 2015 Nov 23. J Clin Oncol. 2016. PMID: 26598744 Free PMC article. Clinical Trial.
Anticancer innovative therapy: Highlights from the ninth annual meeting.
Volpari T, De Santis F, Bracken AP, Pupa SM, Buschbeck M, Wegner A, Di Cosimo S, Lisanti MP, Dotti G, Massaia M, Pruneri G, Anichini A, Fortunato O, De Braud F, Del Vecchio M, Di Nicola M. Volpari T, et al. Among authors: di cosimo s. Cytokine Growth Factor Rev. 2020 Feb;51:1-9. doi: 10.1016/j.cytogfr.2019.12.002. Epub 2019 Dec 13. Cytokine Growth Factor Rev. 2020. PMID: 31862236 Review.
The curious phenomenon of dual-positive circulating cells: Longtime overlooked tumor cells.
Reduzzi C, Vismara M, Gerratana L, Silvestri M, De Braud F, Raspagliesi F, Verzoni E, Di Cosimo S, Locati LD, Cristofanilli M, Daidone MG, Cappelletti V. Reduzzi C, et al. Among authors: di cosimo s. Semin Cancer Biol. 2020 Feb;60:344-350. doi: 10.1016/j.semcancer.2019.10.008. Epub 2019 Oct 15. Semin Cancer Biol. 2020. PMID: 31626958 Free article. Review.
microRNAs in breast cancer development and treatment.
Serpico D, Molino L, Di Cosimo S. Serpico D, et al. Among authors: di cosimo s. Cancer Treat Rev. 2014 Jun;40(5):595-604. doi: 10.1016/j.ctrv.2013.11.002. Epub 2013 Nov 14. Cancer Treat Rev. 2014. PMID: 24286642 Review.
Targeted therapy-induced diarrhea: A review of the literature.
Pessi MA, Zilembo N, Haspinger ER, Molino L, Di Cosimo S, Garassino M, Ripamonti CI. Pessi MA, et al. Among authors: di cosimo s. Crit Rev Oncol Hematol. 2014 May;90(2):165-79. doi: 10.1016/j.critrevonc.2013.11.008. Epub 2013 Dec 5. Crit Rev Oncol Hematol. 2014. PMID: 24373918 Review.
161 results